Business
China deaths reignite debate about using viruses to deliver CRISPR therapies - Endpoints News

What the report says
Two pediatric deaths in Chinese CRISPR trials reignite debate over AAV delivery risks, as many of the 15 genetic-medicine experts Endpoints spoke with point to high viral doses rather than gene editing itself.
Loading debate for this article…
Other publishers covering this story
No additional verified coverage is currently clustered with this report.

Rubanda Launches Shs40m Road Project to Boost Farm-to-Market AccessNile Post
Pearl Bank loan book crosses Shs 1 trillion milestoneThe Observer
UBOS signs MoU with Bugwe, Adhola to strengthen community data collectionThe Observer